Poland· PL-100332006

Abasaglar

A insulin glargine product containing insulinum glarginum, registered in Poland by Eli Lilly Nederland B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC A10AE04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAbasaglarATCA10AE04REGISTER NO.PL-100332006PACKS LISTED13CHECKEDSeptember 27, 2026

Where it is registered

Insulin glargine is registered in 13 of 19 countries.

Countries holding a registration under ATC A10AE04 (insulin glargine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Insulin glargine · ATC A10AE04

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Insulinum glarginum
Manufacturer
Eli Lilly Nederland B.V.
Country
Poland (PL)
ATC code
A10AE04
ATC class
Insulin glargine
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 13

1 priced
  • gtin
    05909991201982
    10 wkł.po 3 ml
    PLN 310.01
  • gtin
    05909991201906
  • gtin
    05909991201913
  • gtin
    05909991201920
  • gtin
    05909991201937
  • gtin
    05909991201944
  • gtin
    05909991201951
  • gtin
    05909991201968
  • gtin
    05909991283223
  • gtin
    05909991283230
  • gtin
    05909991201975
  • gtin
    05909991283209
  • gtin
    05909991283216

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

433 interactions on record for insulin glargine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Insulin glargine · interactions on record

433 records

  • 15 severe
  • 367 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin glargine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin glargine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Abasaglar, Abasaglar Kwikpen
  • Liechtenstein · Abasaglar, Abasaglar Kwikpen
  • Norway · Lantus, Lantus Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b3268cf6-af90-467a-b407-9ad8efcb744e
GET /v1/drugs/b3268cf6-af90-467a-b407-9ad8efcb744e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "100 j.m./ml",
  "packaging": "05909991201906 ¦ Rp ¦ Skasowane ¦ EU/1/14/944/001 ¦ 105785\n1 wkład 3 ml\n05909991201913 ¦ Rp ¦ Skasowane ¦ EU/1/14/944/002 ¦ 105786\n2 wkłady 3 ml\n05909991201920 ¦ Rp ¦ EU/1/14/944/003 ¦ 105787\n5 wkładów 3 ml\n05909991201937 ¦ Rp ¦ Skasowane ¦ EU/1/14/944/004 ¦ 105788\n10 wkładów 3 ml\n05909991201944 ¦ Rp ¦ Skasowane ¦ EU/1/14/944/005 ¦ 105789\n1 wstrzykiwacz 3 ml\n05909991201951 ¦ Rp ¦ Skasowane ¦ EU/1/14/944/006 ¦ 105790\n2 wstrzykiwacze 3 ml\n05909991201968 ¦ Rp ¦ EU/1/14/944/007 ¦ 105791\n5 wstrzykiwacz 3 ml\n05909991201975 ¦ Rp ¦ EU/1/14/944/008 ¦ 105792\n10 wstrzykiwacz 3 ml\n05909991201982 ¦ Rp ¦ EU/1/14/944/009 ¦ 105793\n10 wkładów 3 ml\n05909991283209 ¦ Rp ¦ Skasowane ¦ EU/1/14/944/010 ¦ 116582\n1 wstrzykiwacz 3 ml\n05909991283216 ¦ Rp ¦ Skasowane ¦ EU/1/14/944/011 ¦ 116583\n2 wstrzykiwacz 3 ml\n05909991283223 ¦ Rp ¦ EU/1/14/944/012 ¦ 116584\n5 wstrzykiwacz 3 ml\n05909991283230 ¦ Rp ¦ EU/1/14/944/013 ¦ 116585\n10 wstrzykiwacz 3 ml\nRp ¦ EU/1/14/944/014 ¦ 142397\n5 wstrzykiwaczy 3 ml\nRp ¦ EU/1/14/944/015 ¦ 147353\n10 wstrzyk. 3 ml (opakowanie zbiorcze zawierające 2 opakowania po 5 wstrzykiwaczy)",
  "substance": "Insulinum glargine 100 j.m./ml",
  "common_name": "Insulinum glarginum",
  "pl_product_id": "100332006",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about insulin glargine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.